Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius.
Socié G, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Kolb HJ, Bertz H, Egger M, Grishina O, Finke J; ATG-Fresenius Trial Group. Socié G, et al. Among authors: ottinger hd. Blood. 2011 Jun 9;117(23):6375-82. doi: 10.1182/blood-2011-01-329821. Epub 2011 Apr 5. Blood. 2011. PMID: 21467544 Free article. Clinical Trial.
Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial.
Finke J, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR, Volin L, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Bertz H, Grishina O, Socié G; ATG-Fresenius Trial Group. Finke J, et al. Among authors: ottinger hd. Biol Blood Marrow Transplant. 2012 Nov;18(11):1716-26. doi: 10.1016/j.bbmt.2012.06.001. Epub 2012 Jun 17. Biol Blood Marrow Transplant. 2012. PMID: 22713691 Free article. Clinical Trial.
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Kolb HJ, Bertz H, Egger M, Grishina O, Socié G; ATG-Fresenius Trial Group. Finke J, et al. Among authors: ottinger hd. Lancet Oncol. 2009 Sep;10(9):855-64. doi: 10.1016/S1470-2045(09)70225-6. Epub 2009 Aug 18. Lancet Oncol. 2009. PMID: 19695955 Clinical Trial.
Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial.
Finke J, Schmoor C, Bethge WA, Ottinger H, Stelljes M, Volin L, Heim D, Bertz H, Grishina O, Socie G. Finke J, et al. Lancet Haematol. 2017 Jun;4(6):e293-e301. doi: 10.1016/S2352-3026(17)30081-9. Lancet Haematol. 2017. PMID: 28583289 Clinical Trial.
External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors fails.
Schetelig J, Baldauf H, Heidenreich F, Massalski C, Frank S, Sauter J, Stelljes M, Ayuk FA, Bethge WA, Bug G, Klein S, Wendler S, Lange V, de Wreede LC, Fürst D, Kobbe G, Ottinger HD, Beelen DW, Mytilineos J, Fleischhauer K, Schmidt AH, Bornhäuser M. Schetelig J, et al. Among authors: ottinger hd. Blood. 2020 Apr 16;135(16):1386-1395. doi: 10.1182/blood.2019002887. Blood. 2020. PMID: 31932846 Free PMC article.
Relative Impact of HLA Matching and Non-HLA Donor Characteristics on Outcomes of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Ayuk F, Beelen DW, Bornhäuser M, Stelljes M, Zabelina T, Finke J, Kobbe G, Wolff D, Wagner EM, Christopeit M, Schmid C, Ottinger H, Groth C, Faul C, Bertz H, Rachlis E, Wolschke C, Schetelig J, Horn PA, Mytilineos J, Guellstorf M, Kelsch R, Fleischhauer K, Kröger N, Bethge W. Ayuk F, et al. Biol Blood Marrow Transplant. 2018 Dec;24(12):2558-2567. doi: 10.1016/j.bbmt.2018.06.026. Epub 2018 Jul 24. Biol Blood Marrow Transplant. 2018. PMID: 29966760 Free article.
The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia--a report from the German Registry covering the period from 1998 to 2004.
Bacher U, Klyuchnikov E, Zabelina T, Ottinger H, Beelen DW, Schrezenmeier H, Ehninger G, Müller C, Berger J, Suttorp M, Kolb HJ, Kröger N, Zander AR. Bacher U, et al. Ann Hematol. 2009 Dec;88(12):1237-47. doi: 10.1007/s00277-009-0737-3. Epub 2009 Mar 25. Ann Hematol. 2009. PMID: 19319532 Free article.
Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
Heinzelmann F, Lang PJ, Ottinger H, Faul C, Bethge W, Handgretinger R, Bamberg M, Belka C. Heinzelmann F, et al. Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):523-8. doi: 10.1016/j.ijrobp.2007.06.037. Epub 2007 Sep 14. Int J Radiat Oncol Biol Phys. 2008. PMID: 17869449
Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias.
Beelen DW, Ottinger HD, Ferencik S, Elmaagacli AH, Peceny R, Trenschel R, Grosse-Wilde H. Beelen DW, et al. Among authors: ottinger hd. Blood. 2005 Mar 15;105(6):2594-600. doi: 10.1182/blood-2004-04-1441. Epub 2004 Nov 9. Blood. 2005. PMID: 15536148 Free article.
42 results